MK-789
MK-789 is a competitive reversible inhibitor of dehydropeptidase I (DHP-I). MK-789 competitively blocks the entry of N-formimidoylthienamycin into proximal tubular cells, thereby inhibiting its renal metabolism. MK-789 shifts the renal excretion pathway of N-formimidoylthienamycin to glomerular filtration only, increasing its urinary recovery rate and renal clearance. MK-789 is applicable to studies on renal metabolism and pharmacokinetics.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 85394-14-5
- 分子式: C14H23NO3
- 分子量:253.34
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
MK-789 and its oxidative metabolites inhibit purified dehydropeptidase I in spectrophotometric assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 85394-14-5
-
分子量 253.34
-
分子式 C14H23NO3
-
SMILES
O=C(/C(NC(C1CC1(C)C)=O)=C\CCCCC)O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)